<DOC>
	<DOCNO>NCT02825875</DOCNO>
	<brief_summary>In study aim precisely define clinical utility PSMA imaging across range clinical indication men prostate cancer . To accomplish , make 18F-DCFPyL PET/CT scan available urologist , medical oncologist , radiation oncologist Johns Hopkins survey physicians indication order PET/CT change management occur result new information gain scan . We believe data prove critical planning future study aim evaluate efficacy test improve patient outcome .</brief_summary>
	<brief_title>Study Clinical Utility PSMA Imaging Evaluation Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Willingness sign informed consent 3 . Histologically confirm adenocarcinoma prostate 4 . PSA measurement ≤60 day prior study enrollment 5 . Completed radiographic evaluation wholebody bone scan ( 99mTcMDP Na18F ) crosssectional imaging ( CT MRI ) abdomen pelvis ≤60 day prior study enrollment 1 . Administered radioisotope within 5 physical halflives prior study enrollment 2 . History malignancy diagnose within last 5 year ( exception : low grade urothelial carcinoma bladder , squamous cell carcinoma basal cell carcinoma skin ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>